351003-03-7 Usage
Uses
Used in Pharmaceutical Research:
6-CHLORO-2,3-DIHYDRO-3-OXO-4H-1,4-BENZO& is utilized as a research tool in the pharmaceutical industry for its effects on the central nervous system. It aids in understanding the mechanisms of action and potential therapeutic applications in the treatment of neurological conditions.
Used in Development of Anxiolytic Medications:
In the field of psychopharmacology, 6-CHLORO-2,3-DIHYDRO-3-OXO-4H-1,4-BENZO& is employed as a precursor in the development of new anxiolytic drugs. Its inherent sedative and anxiolytic properties make it a valuable asset in creating medications to manage anxiety disorders and related conditions.
Used in Central Nervous System Studies:
6-CHLORO-2,3-DIHYDRO-3-OXO-4H-1,4-BENZO& is applied in the study of the central nervous system to explore its impact on neurological functions and disorders. This research is crucial for advancing knowledge in neurobiology and for the creation of targeted therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 351003-03-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,0,0 and 3 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 351003-03:
(8*3)+(7*5)+(6*1)+(5*0)+(4*0)+(3*3)+(2*0)+(1*3)=77
77 % 10 = 7
So 351003-03-7 is a valid CAS Registry Number.
InChI:InChI=1/C11H10ClNO4/c12-7-1-2-9-8(5-7)13(4-3-11(15)16)10(14)6-17-9/h1-2,5H,3-4,6H2,(H,15,16)
351003-03-7Relevant academic research and scientific papers
Synthesis and Structure–Activity Relationship Studies of Benzo[b][1,4]oxazin-3(4H)-one Analogues as Inhibitors of Mycobacterial Thymidylate Synthase X
Modranka, Jakub,Li, Jiahong,Parchina, Anastasia,Vanmeert, Michiel,Dumbre, Shrinivas,Salman, Mayla,Myllykallio, Hannu,Becker, Hubert F.,Vanhoutte, Roeland,Margamuljana, Lia,Nguyen, Hoai,Abu El-Asrar, Rania,Rozenski, Jef,Herdewijn, Piet,De Jonghe, Steven,Lescrinier, Eveline
, p. 645 - 662 (2019/02/25)
Since the discovery of a flavin-dependent thymidylate synthase (ThyX or FDTS) that is absent in humans but crucial for DNA biosynthesis in a diverse group of pathogens, the enzyme has been pursued for the development of new antibacterial agents against Mycobacterium tuberculosis, the causative agent of the widespread infectious disease tuberculosis (TB). In response to a growing need for more effective anti-TB drugs, we have built upon our previous screening efforts and report herein an optimization campaign of a novel series of inhibitors with a unique inhibition profile. The inhibitors display competitive inhibition toward the methylene tetrahydrofolate cofactor of ThyX, enabling us to generate a model of the compounds bound to their target, thus offering insight into their structure–activity relationships.
